Last reviewed · How we verify
Paroxetine treatment during 8 weeks — Competitive Intelligence Brief
phase 1
Small molecule
Live · refreshed every 30 min
Target snapshot
Paroxetine treatment during 8 weeks (Paroxetine treatment during 8 weeks) — GlaxoSmithKline.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Paroxetine treatment during 8 weeks TARGET | Paroxetine treatment during 8 weeks | GlaxoSmithKline | phase 1 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Paroxetine treatment during 8 weeks CI watch — RSS
- Paroxetine treatment during 8 weeks CI watch — Atom
- Paroxetine treatment during 8 weeks CI watch — JSON
- Paroxetine treatment during 8 weeks alone — RSS
Cite this brief
Drug Landscape (2026). Paroxetine treatment during 8 weeks — Competitive Intelligence Brief. https://druglandscape.com/ci/paroxetine-treatment-during-8-weeks. Accessed 2026-05-16.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab